Compare Medpace Holdings Inc (MEDP) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Global X Uranium ETF — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Global X Uranium ETF trades at $38.79 (market cap $5.48B). The key difference: Medpace Holdings Inc is far larger — about 3.1× Global X Uranium ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Global X Uranium ETF for 62 Days on average.
| MEDP | URA | |
|---|---|---|
Market Cap | $16.82B | $5.48B |
Volume | 223,093 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $630.19 | $61.81 |
52-Week Low | $393.42 | $37.52 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
URA (Global X Uranium ETF) trades at $38.90, down 2.58% with a bearish technical signal. The ETF faces pressure from recent uranium sector volatility despite positive long-term nuclear energy demand drivers. Key support levels cluster around $37-38 while resistance sits at $39-41. Recent news highlights both opportunities from AI power demand growth and risks from sector-specific headwinds.
The uranium sector faces near-term volatility but benefits from structural tailwinds including AI power demand and global nuclear expansion. Investment opportunities exist through diversified uranium exposure, though risks include commodity price sensitivity and regulatory uncertainty. Current technical weakness suggests cautious entry points may emerge near support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
